Journal Article

Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases

Maderal, Andrea D., Elman, Scott A., Lin, Rachel R., Bray, Eric R., Elgart, George W., Li, Jeffrey N.

2024

Overview

Immune checkpoint inhibitor (ICI) therapies carry the risk of major immune-related adverse events (irAEs). Among the most severe irAEs is epidermal necrosis that may clinically mimic Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN). The aim of this study was to provide a summary of the clinical and histological features of ICI-associated epidermal necrosis, with a special focus on factors associated with fatal outcomes in cases of extensive disease. A total of 98 cases, 2 new cases and 96 reported on PubMed and in the literature, of ICI-associated epidermal necrosis were assessed. Development of epidermal necrosis occurred between 1 day and 3 years after starting ICI therapy, with an average onset of 13.8 weeks for patients with limited (< 30% BSA) and 11.3 weeks for those with extensive (≥ 30% BSA) involvement, and a median onset of 5.8 weeks and 4 weeks respectively. A preceding rash was seen in 52 cases and was more common in extensive cases. Mucosal involvement was only reported in 65% of extensive cases but was significantly associated with fatal reactions. Co-administration of cytotoxic chemotherapy was associated with more extensive disease. Recovery was observed in 96% and 65% of those with limited and extensive involvement respectively and no specific therapy was associated with improved survival. Young age was significantly associated with poor outcomes in extensive disease, the average age of surviving patients was 64.5 years old versus 55.1 years old for deceased patients, p  < 0.01. Both superficial perivascular and interface/lichenoid inflammatory infiltrates were commonly seen. These findings suggest that ICI-associated epidermal necrosis should be considered a distinct clinical entity from drug-induced SJS/TEN.

• Publisher: Springer Berlin Heidelberg,Springer Nature B.V
• Subject: Adult / Aged / Anti-inflammatory agents / Antibiotics / Anticonvulsants / Apheresis / Chemotherapy / Cytotoxicity / Dermatology / Epidermis - drug effects / Epidermis - immunology / Epidermis - pathology / Female / Females / Humans / Immune checkpoint inhibitors / Immune Checkpoint Inhibitors - adverse effects / Immunology / Male / Medical prognosis / Medicine / Medicine & Public Health / Melanoma / Middle Aged / Necrosis / Necrosis - chemically induced / Original Paper / Patients / Pruritus / Radiation / Steroids / Stevens-Johnson syndrome / Stevens-Johnson Syndrome - diagnosis / Stevens-Johnson Syndrome - etiology / Stevens-Johnson Syndrome - immunology / Stevens-Johnson Syndrome - pathology / Tumor necrosis factor-TNF / Urogenital system